VENMAX
Venmax Drugs And Pharmaceuticals financials
- Market cap
- ₹29 Cr
Quarterly results
Q1 FY27: revenue up 105.0%, net profit up 200.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 1 +676% | 2 +675% | 4 +1094% | 2 +105% |
| EBITDA | -0 | -0 | -0 | 0 | 0 +117% | -0 +94% | 0 +108% | 0 +200% |
| Net profit | -0 | -0 | 1 | 0 | 0 +107% | 0 +106% | 0 −86% | 0 +200% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −40.6% 1Y
1Y: ₹25.2 on 9 Sept 2025 → ₹14.98. High ₹30.1 (2 Dec 2025), low ₹13.93 (2 Sept 2026).
Financials, as filed
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹0 Cr | ₹1 Cr | ₹8 Cr |
| Operating profit | ₹-0 Cr | ₹-1 Cr | ₹0 Cr |
| Operating margin | — | -131.2% | 1.0% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹0 Cr | ₹-0 Cr | ₹0 Cr |
| Net margin | — | -1.2% | 2.5% |
| Cash from operations | ₹0 Cr | ₹-2 Cr | ₹-11 Cr |
| Free cash flow | ₹0 Cr | ₹-2 Cr | ₹-11 Cr |
| ROCE | — | -1.0% | 3.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹8 Cr | ₹12 Cr |
| Reserves | ₹-8 Cr | ₹-6 Cr | ₹-6 Cr | ₹-6 Cr | ₹1 Cr | ₹3 Cr |
| Borrowings | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹0 Cr |
| Other liabilities | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹2 Cr | ₹2 Cr |
| Total liabilities | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹14 Cr | ₹16 Cr |
| Fixed assets | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹14 Cr | ₹16 Cr |
| Total assets | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹14 Cr | ₹16 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters trimmed −12.67 pp while the public added +12.66 pp. The shareholder count grew 2% to 6,865.
- Promoters
- 10.5%
- Public
- 89.5%
Since Jun 2025
- Promoters −12.67 pp
- Public +12.66 pp
- DIIs 0.00 pp
How it drifted, 12 quarters
Over this window the public went from 76.7% to 89.5% — +12.8 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 23.1%, DIIs 0.1%, Public 76.7%.Dec '23: Promoters 23.1%, DIIs 0.1%, Public 76.7%.Mar '24: Promoters 23.1%, DIIs 0.1%, Public 76.7%.Jun '24: Promoters 23.1%, DIIs 0.1%, Public 76.7%.Sep '24: Promoters 23.1%, DIIs 0.1%, Public 76.7%.Dec '24: Promoters 23.1%, DIIs 0.1%, Public 76.7%.Mar '25: Promoters 23.1%, DIIs 0.1%, Public 76.7%.Jun '25: Promoters 23.1%, Public 76.9%.Sep '25: Promoters 23.1%, Public 76.9%.Dec '25: Promoters 15.1%, Public 84.9%.Mar '26: Promoters 13.8%, Public 86.2%.Jun '26: Promoters 10.5%, Public 89.5%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Pushpa Bhaju newly disclosed 12.95% held
- Jugal Kishore Bhagat newly disclosed 11.22% held
The same filing shows 15 holders trimming and 12 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Venmax Drugs And Pharmaceuticals Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Pushpa Bhaju | 12.95% | newly disclosed |
| Jugal Kishore Bhagat | 11.22% | newly disclosed |
| Venkat Narender Nuka | 8.00% | −2.55 pp |
| Manish Grover | 4.75% | −1.51 pp |
| Percy Homi Italia | 4.02% | −1.29 pp |
| Wca Services Private Limited | 3.48% | −1.11 pp |
| Mega Flex Plastics Limited | 2.59% | −0.83 pp |
| Dr Tadla Tirumal Rao | 2.33% | −0.74 pp |
| Shammi Khanna | 2.16% | −0.69 pp |
| J Muralidharan | 1.73% | −0.55 pp |
| Dwarka Prasad Gattani | 1.73% | −0.55 pp |
| Sampati Devi Jain | 1.73% | −0.55 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Venmax Drugs And Pharmaceuticals Ltd
Guides on how to read this kind of business and the numbers that matter.